All In Biotech

NDA 020411 · Ferring Pharms INC

Cervidil

Dinoprostone · Vaginal · Prostaglandin Analog

Last checked: Nov 20, 2026Latest source record: Jul 7, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Mar 30, 1995

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

30 Phase 3, 9 recruiting

FAERS reports

769

660 serious, 46 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 2, 2023.

CERVIDIL is indicated for the initiation and/or continuation of cervical ripening in pregnant women at or near term in whom there is a medical or obstetrical indication for the induction of labor. CERVIDIL is a prostaglandin analog indicated for the initiation and/or continuation of cervical ripening in pregnant women at or near term in whom there is a medical or obstetrical indication for the induction of labor. ( 1 )

Mechanism: Dinoprostone is found in low concentrations in most tissues of the body and functions as a local hormone. In pregnancy, dinoprostone is secreted continuously by the fetal membranes and placenta and plays an important role in the final events leading to the initiation of labor including cervical ripening. Dinoprostone stimulates the production of prostaglandin F 2α ( PGF 2α), which sensitizes the myometrium to endogenous or exogenously administered oxytocin. Available evidence indicates that dinoprostone, in the concentrations found during the early part of labor, plays an important role in...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 30, 1995 Original approval · Type 3 - New Dosage Form
1 products under this application
  • CERVIDIL · DINOPROSTONE 10MG · INSERT, EXTENDED RELEASE, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dinoprostone" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal exposure during pregnancy127
  • drug exposure during pregnancy70
  • exposure during pregnancy70
  • caesarean section63
  • maternal exposure during pregnancy58
  • premature separation of placenta47
  • off label use44
  • uterine hyperstimulation41
  • drug ineffective36
  • premature baby35
  • haemoglobin decreased33
  • premature delivery33

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
20058
200624
200710
200829
20099
20105
201118
201215
201321
201413
201518
201636
201750
201858
201939
202046
202154
202266
202395
202454
202554
202638

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 255 on PubMed

Sponsor: Ferring Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.